As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma.
Please note that following on from advice received from the company the timelines for this appraisal remain to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.